A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism—A Proof-of-Concept Trial

Новый моноклональный антитело против CD40 — исцалимаб — для контроля гипертиреоза при болезни Грейвса: доказательное исследование
Craig T. Basson, James S. Rush, Marius Nicolae Stan, Yanling He, George Jean Kahaly, Pascal Espié, Lara Frommer, Péter Attila Gergely, Laurence Colin, Ahmed Amer, Imelda Schuhmann, Yanling He, Laurence Colin, Ahmed Amer
2019-09-12

CD40-CD154 co-stimulatory pathwayGraves diseaseIscalimabanti-CD40 monoclonal antibodyphase II proof-of-concept trial
CONTEXT: The CD40-CD154 co-stimulatory pathway plays an important role in the pathogenesis of Graves disease (GD) by promoting autoreactive B-cell activation. OBJECTIVE: Evaluate efficacy and safety of a human, blocking, nondepleting anti-CD40 monoclonal antibody, iscalimab, in hyperthyroid patients with GD. DESIGN: Open-label, phase II proof-of-concept study. SETTING: Multicenter. PATIENTS: Fifteen with GD. INTERVENTION: Patients received 5 doses of iscalimab at 10 mg/kg intravenously over 12 weeks. MAIN OUTCOME MEASURES: Thyroid-related hormones and autoantibodies, plasma soluble CD40, free CD40 on B cells, soluble CXCL13, pharmacokinetics, and safety were assessed. RESULTS: The iscalimab intervention resulted in complete CD40 engagement for up to 20 weeks. A clinical response and biochemical euthyroidism was observed in 7 of 15 (47%) patients. Free and total triiodothyronine and thyroxine normalized in 7 patients who did not receive any rescue medication with antithyroid drugs (ATD), and 2/15 (13.3%) showed normal thyrotropin. Six (40%) patients required ATD. Four of 7 responders relapsed after treatment completion. Serum concentrations of thyrotropin receptor autoantibodies (TSH-R-Ab) significantly declined in all patients (mean 15.3 IU/L vs 4.0 IU/L, 66% reduction; P < 0.001) and TSH-R-Ab levels normalized in 4 (27%). Thyroperoxidase and thyroglobulin autoantibodies significantly decreased in responders. Iscalimab rapidly reduced serum CXCL13 concentrations (P < 0.001). Twelve (80.0%) patients reported at least 1 adverse event (AE). All treatment-related AE were mild or moderate and resolved by end of the study. CONCLUSION: Iscalimab was generally safe and clinically effective in a subgroup of hyperthyroid GD patients. The potential therapeutic benefit of iscalimab should be further tested.
1
Four of the seven initial responders relapsed after treatment completion, indicating incomplete durability of response.
2
In an open-label phase II study of 15 Graves disease patients, 7 of 15 (47%) achieved clinical response and biochemical euthyroidism without rescue antithyroid drugs.
3
Iscalimab rapidly and significantly reduced serum CXCL13 concentrations (P < 0.001), a biomarker associated with B-cell activity.
4
Iscalimab was generally safe: 12 of 15 (80%) patients reported at least one adverse event, all treatment-related events were mild or moderate and resolved by study end.
5
Iscalimab, a human blocking nondepleting anti-CD40 monoclonal antibody, achieved complete CD40 engagement for up to 20 weeks after treatment.
6
Thyroid hormones (free and total T3 and T4) normalized in the 7 responders who did not receive rescue medication; TSH normalized in 2 of 15 (13.3%).
7
Thyroperoxidase and thyroglobulin autoantibodies decreased significantly in treatment responders.
8
Thyrotropin receptor autoantibodies (TSH-R-Ab) declined significantly across all patients (mean 15.3 IU/L to 4.0 IU/L, 66% reduction; P < 0.001), normalizing in 4 patients (27%).

Iscalimab (a human, blocking, nondepleting anti-CD40 monoclonal antibody) administered to patients with Graves hyperthyroidism

Efficacy and safety of iscalimab for controlling hyperthyroidism in Graves disease, including effects on thyroid hormones, thyroid autoantibodies (TSH-R-Ab, TPO, Tg), CD40 engagement, CXCL13 levels, pharmacokinetics, and adverse events

Publication Details
Publication Date
2019-09-12
Journal
Publisher
ISSN
Cited by
100
Access Type
Author Information
Authors
Craig T. Basson
James S. Rush
Marius Nicolae Stan
Yanling He
George Jean Kahaly
Pascal Espié
Lara Frommer
Péter Attila Gergely
Laurence Colin
Ahmed Amer
Imelda Schuhmann
Yanling He
Laurence Colin
Ahmed Amer
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%